Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)

ABSTRACT: This observational study will assess the treatment duration, progression-free survival, reason for stopping treatment and patient and tumor characteristics of bevacizumab [Avastin] treatment in patients with metastatic colorectal cancer. Data will be collected for approximately 34 months. The target sample size is >300 patients.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2086510 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR